Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 5/20 | 0.36 |
| ▸ | ADCY5 | O95622 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | NRP1 | O14786 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8464539 | 0.89 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| SCHEMBL8464552 | 0.89 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| Bch-1393 SCHEMBL4983771 | 0.87 | CYP1A2 (0.41) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| Bch-1393 SCHEMBL14203135 | 0.87 | CYP1A2 (0.41) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| Bch-1393 SCHEMBL8466563 | 0.87 | CYP1A2 (0.41) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| SCHEMBL8464129 | 0.86 | CYP1A2 (0.42) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| SCHEMBL8467088 | 0.86 | CYP1A2 (0.42) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| SCHEMBL29769282 | 0.84 | HPRT1 (0.45) | C3AR1 | |
| SCHEMBL8464634 | 0.81 | CYP1A2 (0.49) | CYP1A2CYP2D6MAPK1ADCY5 | |
| SCHEMBL8467074 | 0.75 | P2RY1 (0.43) | ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3554435-B1 | SYSTEMS FOR DELIVERING DRUGS TO RETINAL TISSUE | CLEARSIDE BIOMEDICAL INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250152413-A1 | SYSTEMS, DEVICES, AND METHODS FOR NEEDLE-LESS OCULAR INJECTIONS | CLEARSIDE BIOMEDICAL INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-3721872-B1 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | CLEARSIDE BIOMEDICAL INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12201558-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12127975-B2 | Devices and methods for adjusting the insertion depth of a needle for medicament delivery | CLEARSIDE BIOMEDICAL, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-3496680-B1 | DEVICE FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-110302004-B | Apparatus and method for ocular injection | 科尼尔赛德生物医学公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230083551-A1 | Formulations for the Suprachoroidal Space of an Eye and Methods | EMORY UNIVERSITY | 2023-03-16 | — | — | US | disclosed |
| US-11596545-B2 | Systems and methods for ocular drug delivery | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-11559428-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-2887982-B1 | APPARATUS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE BIOMEDICAL INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11504431-B2 | Formulations for the suprachoroidal space of an eye and methods | EMORY UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220280341-A1 | APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE ROYALTY LLC | 2022-09-08 | — | — | US | disclosed |
| US-20220280386-A1 | METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER | CLEARSIDE BIOMEDICAL, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | CYP1A2 2507/4885CYP2D6 3089/4885MAPK1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.